Intellia Therapeutics (NTLA) Competitors $12.17 -0.08 (-0.65%) Closing price 04:00 PM EasternExtended Trading$12.12 -0.05 (-0.41%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NTLA vs. SWTX, BHVN, RXRX, PTCT, OGN, RARE, ALVO, RNA, ADMA, and ACLXShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Avidity Biosciences (RNA), ADMA Biologics (ADMA), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. SpringWorks Therapeutics Biohaven Recursion Pharmaceuticals PTC Therapeutics Organon & Co. Ultragenyx Pharmaceutical Alvotech Avidity Biosciences ADMA Biologics Arcellx Intellia Therapeutics (NASDAQ:NTLA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk. Which has more volatility and risk, NTLA or SWTX? Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Which has stronger valuation & earnings, NTLA or SWTX? SpringWorks Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$36.28M35.14-$481.19M-$5.44-2.30SpringWorks Therapeutics$5.45M817.40-$325.10M-$3.88-15.43 Is NTLA or SWTX more profitable? Intellia Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -203.09%. SpringWorks Therapeutics' return on equity of -48.21% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% SpringWorks Therapeutics -203.09%-48.21%-42.19% Do insiders & institutionals believe in NTLA or SWTX? 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.2% of Intellia Therapeutics shares are held by company insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor NTLA or SWTX? Intellia Therapeutics received 333 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 71.43% of users gave SpringWorks Therapeutics an outperform vote while only 69.09% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes43869.09% Underperform Votes19630.91% SpringWorks TherapeuticsOutperform Votes10571.43% Underperform Votes4228.57% Do analysts rate NTLA or SWTX? Intellia Therapeutics presently has a consensus price target of $48.71, suggesting a potential upside of 289.09%. SpringWorks Therapeutics has a consensus price target of $71.50, suggesting a potential upside of 19.40%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to NTLA or SWTX? In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 26 mentions for SpringWorks Therapeutics and 24 mentions for Intellia Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.27 beat Intellia Therapeutics' score of 0.10 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SpringWorks Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIntellia Therapeutics beats SpringWorks Therapeutics on 10 of the 19 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$2.30B$5.84B$9.20BDividend YieldN/A0.75%4.78%3.85%P/E Ratio-2.302.4316.3214.14Price / Sales35.1487.17461.0479.70Price / CashN/A15.7944.0437.47Price / Book1.073.327.794.78Net Income-$481.19M-$65.73M$3.18B$245.88M7 Day Performance16.99%-1.87%-0.52%-0.90%1 Month Performance25.94%-7.18%1.80%-0.52%1 Year Performance-53.43%-13.51%18.90%16.50% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.4758 of 5 stars$12.17-0.7%$48.71+300.2%-54.9%$1.24B$36.28M-2.24600News CoverageGap UpSWTXSpringWorks Therapeutics1.2638 of 5 stars$57.43-2.0%$70.83+23.3%+22.8%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.3782 of 5 stars$41.45-0.8%$63.15+52.4%-15.8%$4.19BN/A-4.43239Short Interest ↓RXRXRecursion Pharmaceuticals1.539 of 5 stars$10.53+23.9%$8.75-16.9%-17.8%$4.11B$64.60M-6.88400Gap UpHigh Trading VolumePTCTPTC Therapeutics3.6367 of 5 stars$51.82+4.3%$58.85+13.6%+93.9%$4.00B$937.82M-8.721,410Analyst ForecastNews CoverageOGNOrganon & Co.4.8682 of 5 stars$15.30-6.3%$20.80+36.0%-15.2%$3.94B$6.26B3.0310,000RAREUltragenyx Pharmaceutical4.6169 of 5 stars$42.49-2.4%$92.43+117.5%-7.1%$3.92B$434.25M-6.571,276Analyst ForecastALVOAlvotech2.4243 of 5 stars$12.99+1.6%$18.00+38.6%-26.7%$3.92B$391.87M-7.021,026News CoverageRNAAvidity Biosciences1.6464 of 5 stars$32.31-2.2%$65.80+103.7%+132.7%$3.85B$9.56M-11.22190ADMAADMA Biologics3.5624 of 5 stars$15.90-1.1%$21.25+33.6%+212.2%$3.76B$258.21M56.79530ACLXArcellx2.0381 of 5 stars$65.23+2.4%$105.93+62.4%+9.5%$3.53B$155.82M-91.8780Upcoming Earnings Related Companies and Tools Related Companies SpringWorks Therapeutics Alternatives Biohaven Alternatives Recursion Pharmaceuticals Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Ultragenyx Pharmaceutical Alternatives Alvotech Alternatives Avidity Biosciences Alternatives ADMA Biologics Alternatives Arcellx Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NTLA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
